Cyclo Therapeutics Inc (CYTH) - News Archive

Unraveling Hope in Tiny Hearts: Cyclo Therapeutics Unveils Promising Phase 3 Data for NPC1 Treatment In a heartfelt juncture of science and compassion, Cyclo Therapeutics, Inc. (Nasdaq: CYTH) continues to blaze a trail...

Groundbreaking Progress in Niemann-Pick Disease Type C1 Treatment: Cyclo Therapeutics Reports Promising Data from Phase 3 Study In an age where biomedical innovation is key to developing effective treatments for rare an...

CSIMarket.com News In a significant move that aims to make transformative strides in biotechnology, Rafael Holdings, Inc. (NYSE: RFL) and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) have announced a definitive merger agreem...

Cyclo Therapeutics: A Transformative Second Quarter Amid Pivotal Milestones and Financial DevelopmentsGainesville, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company committed to develo...

Gainesville, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology firm committed to developing transformative medicines through cutting-edge scientific research, today announced a significant mil...

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment in Phase 3 Trial for Niemann-Pick DiseaseIn the bustling biotech sector, every milestone achieved in clinical trials represents a leap forward...

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateIn a recent announcement, Cyclo Therapeutics, a clinical stage biotechnology company, shared its financial results for the firs...